Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | SMO | Q99835 | 3/20 | 0.59 |
| ▸ | TYK2 | P29597 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369780 | 0.85 | CYP1A2 (0.59) | CYP1A2HPGDCYP2C19POLBSMO | |
| SCHEMBL7885319 | 0.85 | CYP1A2 (0.59) | CYP1A2HPGDCYP2C19POLBSMO | |
| SCHEMBL29706661 | 0.80 | MEN1 (0.59) | MEN1LMNAKMT2ARAB9A | |
| SCHEMBL1203522 | 0.80 | SMO (0.80) | CYP1A2HPGDCYP2C19POLBSMO | |
| SCHEMBL1437928 | 0.80 | KMT2A (0.80) | HPGDSMOTYK2MEN1LMNA | |
| SCHEMBL8373805 | 0.79 | POLB (1.00) | CYP1A2HPGDCYP2C19POLBSMO | |
| Water SCHEMBL27602058 | 0.78 | SMO (0.77) | CYP1A2HPGDCYP2C19POLBSMO | |
| SCHEMBL2117583 | 0.77 | SMO (0.75) | CYP1A2HPGDCYP2C19POLBSMO | |
| SCHEMBL1882550 | 0.77 | POLB (0.72) | CYP1A2HPGDCYP2C19POLBSMO | |
| SCHEMBL297513 | 0.77 | POLB (0.72) | CYP1A2HPGDCYP2C19POLBSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021092-A1 | STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021092-A1 | STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE | SNCA, MAPT, PSEN2 | CYP1A2 1143/4885HPGD 4835/4885CYP2C19 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.